These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31672491)

  • 21. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
    Yuan B; Ji W; Xia H; Li J
    Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
    Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
    Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma.
    Jess J; Sorensen KM; Boguslawski EA; Stout MC; Madaj ZB; Caiello BP; Pomaville M; Wilson ER; Kinn-Gurzo SS; Parker CC; Veluvolu SM; Brysgel TV; Kaufman R; Kitchen-Goosen SM; Gedminas JM; Grohar PJ
    Clin Cancer Res; 2024 Aug; 30(16):3533-3548. PubMed ID: 38506712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
    Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
    Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
    Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
    Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
    Subbiah V; Brown RE; Jiang Y; Buryanek J; Hayes-Jordan A; Kurzrock R; Anderson PM
    PLoS One; 2013; 8(7):e68985. PubMed ID: 23922674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
    Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
    Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
    Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
    Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
    Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.
    Caropreso V; Darvishi E; Turbyville TJ; Ratnayake R; Grohar PJ; McMahon JB; Woldemichael GM
    J Biol Chem; 2016 May; 291(19):10058-66. PubMed ID: 26961871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
    Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
    Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
    Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
    Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.
    Souza BK; da Costa Lopez PL; Menegotto PR; Vieira IA; Kersting N; Abujamra AL; Brunetto AT; Brunetto AL; Gregianin L; de Farias CB; Thiele CJ; Roesler R
    Mol Neurobiol; 2018 Sep; 55(9):7242-7258. PubMed ID: 29397557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.